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FK 506 is a new immunosuppressive agent that has been used successfully in human organ transplanta-
tiori. 1 This agent has a favorable profile on pancreatic islets 
studied in vitro2; however. in high concentrations. it may 
suppress insulin release from both rodentJ .4 and human 
islets3 studied in vitro. More importantly, a diabetogenic 
effect of this agent has been reported in man.5•6 Since this 
agent may have potential application in the field of pan-
creas and islet cell transplantation. we examined the effect 
of FK 506 on glucose metabolism and glucose-induced 
insulin release using the model of human islets trans-
planted into male balb/c nude mice. 7 
METHODS 
Human Islet Isolation 
Human islets were prepared from cadaveric donor pancreata 
obtained from multiorgan donors. 8.9 After in situ perfusion of the 
abdominal aorta with UniversIty of WisconSin (UW) solution. the 
pancreas was transported on ice. The islets were isolated using the 
automated method as previously described. IO·\\ 
Transplantation 
Male balb/c mIce (n = 2S) (16 to 20 g) were made diabetic by a 
single IV injection of streptozotocin (l6S mgtkg). Diabetes was 
confirmed if random plasma glucose following the injection was 
>400 mg/dL. Three to S days later. each animal received an 
aliquot of approxImately 600 ISO-/Lfll human islet equivalents that 
were transplanted beneath the left renal capsule. 7 
FK S06 (10 mg) was dissolved fresh daily in a mixture of 
Cremaphor (625 mg) and ethanol (328 mg). This solution was 
diluted with normal saline to gIve a final FK 506 concentration of 
\00 mgtmL. 
Seven days after human islet transplantallon. the animals were 
randomly assigned to four groups. Group A (n = 10) animals 
received 7 daily IP injections of O.S mL of Cremaphor-ethanol-
saline vehicle. Group B (n = 5) animals were treated by 7 daily IP 
injections of 0.3 mgtkg FK 506. Groups C (n = 5) and D (n = 5) 
animals received 7 daily injections of I and 3 mg/kg FK 506. 
respective I y. 
Metabolic Testing 
Fifteen days after human islet transplantation. the animals under-
went a standard IP glucose tolerance test (lPGrn. \2 Following an 
overnIght fast. the animals were injected wllh 2 glkg IP of a 25% 
glucose solution. Samples were obtained for analysis of plasma 
glucose and C-peptide at O. 15. 30. and 60 minutes following the IP 
injeCtion. C-pepudc was measured by standard radioimmunoas-
say using human C-peptide standards. 
Immediately following IPGTI. the animals in groups B. C. and 
D were killed. and blood was collected for determination of FK 
506 levels using an enzyme Immunoassay (Fujisawa Pharmaceu-
ticals Co. Osaka. Japan). 
Histologic Studies 
The kidneys bearing human islet transplants were excised for 
determination of morphologic integrity of the grafts. In group A 
(control). a nephrectomy of the kidney bearing the graft was 
performed to demonstrate that the human islet transplants were 
responsible for the maintenance of normoglycemia. Histologic 
integrity of the renal subcapsular graft was determined by hema. 
toxylin-cosin stain and by immunoperoxidase (insulin) stain. Re-
sults are expressed as mean: SEM. and analysis of significance 
of difference was assessed by Student's t test. 
RESULTS 
Administration of 0.3 mgikg per day of FK 506 for 1 We 
did not produce any significant alteration of glucose disac· 
pearance. Animals receiving 1 and 3 mglkg per day FK 506 
had a significant delay in plasma glucose disappearance 
rate. In addition, 2 of 10 animals in these groups had a 
fasting glucose> 200 mgidL. The abnormal glucose disap-
pearance rate in group 0 was associated with impairment 
of insulin secretion from the engra(ted islets. Fifteen 
minutes after glucose injection. a decreased C-peptide 
level compared to control group A was observed (1.01 ± 
0.25 vs 2.07 ± 0.38) (P < .03). 
Plasma FK 506 levels were 3.8 ± 1.25 ngimL (group B). 
106.6 ± 2.82 ngimL (group C), and 303.5 : 77.7 nglmL 
(group 0) (P < .05). 
Histologic studies indicated that human islets were 
present in the renal subcapsular space of all transplamel! 
animals. In the two animals (I in group C and 1 in group 0 I 
that had fasting hyperglycemia. the {3 cells appeared de-
granulated. In the remaining animals. human islets ap-
peared well preserved with no significant difference be-
tween FK 506-treated and control animals. Nephrectomy 
produced a rapid return to the diabetic state. indicating 
that the transplanted human islets were responsible for 
maintaining normoglycemia. 
From the Department of Surgery, University Health Center of 
Pittsburgh, University of Pittsburgh, and the Veterans Administra-
tion Medical Center, Pittsburgh, Pennsylvanla and the Diabetes 
Research Institute, University of Miami. Miami. Florida. 
Supported by research grants from the Veterans Administration 
and Project Grant No. OK 29961 from the National Institutes of 
Health, Bethesda, Maryland. 
Address repnnt requests to Camillo Ricordi. MD. Department of 
Surgery, 3601 Fifth Avenue, University of Pittsburgh. Pittsburgh, 
PA 15213. 
~ 1991 by Appleton & Lange 
0041-13451911$3.001 +0 
3164 TransplantatIOn Proceedings. Vol 23. No 6 (December). 1991: pp 3164-{3165 
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. The data indicate that FK 506 did not produce a signif-
alteration of glucose homeostasis in animals treated 
a dose of 0.3 mgtkg per day for 7 days. Nevertheless. 
prolonged glucose disappearance was observed in the 
groups that received higher FK 506 doses. These effects 
appear to be dose dependent. and were observed at serum 
FK levels that are significantly higher than therapeutic 
levels achieved in man to.5 to 3 ngimL). Furthermore. in 
the group that received the highest dose of FK 506. a small 
decrease in insulin secretion was observed. 
These findings in vivo confirm the results of previous 
reports that high concentrations of FK 506 inhibit insulin 
secretion from rat and human islets in vitro.J.4 Both 
: metabolic and histologic findings confirm a lack of signifi-
- cant toxic effects of FK 506 on islets. l Further studies are 
required to assess if FK 506 has an effect to increase 
insulin resistance that would explain the diabetogenic 
elIect observed in vivo. 
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